Mitotane induces CYP3A4 expression via activation of the steroid and xenobiotic receptor

Journal of Endocrinology

Volumn 216, Issue 3, 2013, Pages 297-305

  Takeshita, Akira ^a   Igarashi Migitaka, Junko ^b   Koibuchi, Noriyuki ^c   Takeuchi, Yasuhiro ^a  

^a TORANOMON HOSPITAL   (Japan)

^b ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Adrenocortical carcinoma; CYP3A4; Mitotane; SXR

Indexed keywords

CYTOCHROME P450 3A4; LUCIFERASE; MESSENGER RNA; MITOTANE; STEROID RECEPTOR; STEROID RECEPTOR COACTIVATOR 1; XENOBIOTIC AGENT;

ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; LIGAND BINDING; LIVER CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; REAL TIME POLYMERASE CHAIN REACTION; XENOBIOTIC METABOLISM;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; CELL LINE, TUMOR; CYTOCHROME P-450 CYP3A; FEMALE; HEPATOCYTES; HUMANS; MALE; MIDDLE AGED; MITOTANE; RECEPTORS, STEROID;

EID: 84875068550     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1530/JOE-12-0297     Document Type: Article

References (26)

1. Allolio B & Fassnacht M 2006 Clinical review: adrenocortical carcinoma: clinical update. Journal of Clinical Endocrinology and Metabolism 91 2027-2037. (doi:10.1210/jc.2005-2639)
2. Cohen RN, Putney A, Wondisford FE & Hollenberg AN 2000 The nuclear corepressors recognize distinct nuclear receptor complexes. Molecular Endocrinology 14 900-914. (doi:10.1210/me.14.6.900)
3. Cuddy PG & Loftus LS 1986 Influence of mitotane on the hypoprothrombinemic effect of warfarin. Southern Medical Journal 79 387-388. (doi:10.1097/00007611-198603000-00037)
4. van Erp NP, Guchelaar HJ, Ploeger BA, Romijn JA, Hartigh J & Gelderblom H 2011 Mitotane has a strong and a durable inducing effect on CYP3A4 activity. European Journal of Endocrinology 164 621-626. (doi:10.1530/EJE-10-0956)
5. Fassnacht M, Terzolo M, Allolio B, Baudin E, Haak H, Berruti A, Welin S, Schade-Brittinger C, Lacroix A, Jarzab B et al. 2012 Combination chemotherapy in advanced adrenocortical carcinoma. New England Journal of Medicine 366 2189-2197. (doi:10.1056/NEJMoa1200966)
6. Fukushima DK, Bradlow HL & Hellman L 1971 Effects of o,p0-DDD on cortisol and 6-beta-hydroxycortisol secretion and metabolism in man. Journal of Clinical Endocrinology and Metabolism 32 192-200. (doi:10.1210/jcem-32-2-192)
7. Gao J & Xie W 2010 Pregnane X receptor and constitutive androstane receptor at the crossroads of drug metabolism and energy metabolism. Drug Metabolism and Disposition 38 2091-2095. (doi:10.1124/dmd.110. 035568)
8. Goodwin B, Hodgson E & Liddle C 1999 The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Molecular Pharmacology 56 1329-1339.
9. Hague RV, May W & Cullen DR 1989 Hepatic microsomal enzyme induction and adrenal crisis due to o,p'DDD therapy for metastatic adrenocortical carcinoma. Clinical Endocrinology 31 51-57. (doi:10.1111/j.1365-2265.1989.tb00453.x)
10. Kanebratt KP & Andersson TB 2008 HepaRG cells as an in vitro model for evaluation of cytochrome P450 induction in humans. Drug Metabolism and Disposition 36 137-145. (doi:10.1124/dmd.107.017418)
11. Kliewer SA, Goodwin B & Willson TM 2002 The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocrine Reviews 23 687-702. (doi:10.1210/er.2001-0038)
12. Kroiss M, Quinkler M, Lutz WK, Allolio B & Fassnacht M 2011 Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma. Clinical Endocrinology 75 585-591. (doi:10.1111/j.1365-2265.2011.04214.x)
13. Maglich JM, Parks DJ, Moore LB, Collins JL, Goodwin B, Billin AN, Stoltz CA, Kliewer SA, Lambert MH, Willson TM et al. 2003 Identification of a novel human constitutive androstane receptor (CAR) agonist and its use in the identification of CAR target genes. Journal of Biological Chemistry 278 17277-17283. (doi:10.1074/jbc. M300138200)
14. Medina-Diaz IM & Elizondo G 2005 Transcriptional induction of CYP3A4 by o,p0-DDT in HepG2 cells. Toxicology Letters 157 41-47. (doi:10.1016/ j.toxlet.2005.01.003)
15. Medina-Diaz IM, Arteaga-Illan G, de Leon MB, Cisneros B, Sierra-Santoyo A, Vega L, Gonzalez FJ & Elizondo G 2007 Pregnane X receptor-dependent induction of the CYP3A4 gene by o,p0-1,1,1,-trichloro-2,2-bis (p-chlorophenyl)ethane. Drug Metabolism and Disposition 35 95-102. (doi:10.1124/dmd.106.011759)
16. Naspinski C, Gu X, Zhou GD, Mertens-Talcott SU, Donnelly KC & Tian Y 2008 Pregnane X receptor protects HepG2 cells from BaP-induced DNA damage. Toxicological Sciences 104 67-73. (doi:10.1093/toxsci/kfn058)
17. Robinson BG, Hales IB, Henniker AJ, Ho K, Luttrell BM, Smee IR & Stiel JN 1987 The effect of o,p0-DDD on adrenal steroid replacement therapy requirements. Clinical Endocrinology 27 437-444. (doi:10.1111/j.1365-2265.1987.tb01171.x)
18. Smith CL & O'Malley BW 2004 Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocrine Reviews 25 45-71. (doi:10.1210/er.2003-0023)
19. Takeshita A, Inagaki K, Igarashi-Migitaka J, Ozawa Y & Koibuchi N 2006 The endocrine disrupting chemical, diethylhexyl phthalate, activates MDR1 gene expression in human colon cancer LS174T cells. Journal of Endocrinology 190 897-902. (doi:10.1677/joe.1.06664)
20. Takeshita A, Igarashi-Migitaka J, Nishiyama K, Takahashi H, Takeuchi Y & Koibuchi N 2011 Acetyl tributyl citrate, the most widely used phthalate substitute plasticizer, induces cytochrome p450 3a through steroid and xenobiotic receptor. Toxicological Sciences 123 460-470. (doi:10.1093/ toxsci/kfr178)
21. Tolson AH & Wang H 2010 Regulation of drug-metabolizing enzymes by xenobiotic receptors: PXR and CAR. Advanced Drug Delivery Reviews 62 1238-1249. (doi:10.1016/j.addr.2010.08.006)
22. Wang H & Tompkins LM 2008 CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Current Drug Metabolism 9 598-610. (doi:10.2174/138920008785821710)
23. Watkins RE, Wisely GB, Moore LB, Collins JL, Lambert MH, Williams SP, Willson TM, Kliewer SA & Redinbo MR 2001 The human nuclear xenobiotic receptor PXR: structural determinants of directed promiscuity. Science 292 2329-2333. (doi:10.1126/science.1060762)
24. Zhang B, XieW& KrasowskiMD 2008 PXR: a xenobiotic receptor of diverse function implicated in pharmacogenetics. Pharmacogenomics 9 1695-1709. (doi:10.2217/14622416.9.11.1695)
25. Zhou C, Verma S & Blumberg B 2009 The steroid and xenobiotic receptor (SXR), beyond xenobiotic metabolism. Nuclear Receptor Signaling 7 e001. (doi:10.1621/nrs.07001)
26. Zucchini N, de Sousa G, Bailly-Maitre B, Gugenheim J, Bars R, Lemaire G & Rahmani R 2005 Regulation of Bcl-2 and Bcl-xL anti-apoptotic protein expression by nuclear receptor PXR in primary cultures of human and rat hepatocytes. Biochimica et Biophysica Acta 1745 48-58. (doi:10.1016/ j.bbamcr.2005.02.005)